Ionic cross-linked starch hemostatic powder as well as preparation method and application thereof

By adding metal ions to a starch solution to form flocculents and preparing ion-crosslinked starch hemostatic powder, the problems of complex preparation and environmental unfriendliness of existing starch hemostatic materials are solved, and a starch hemostatic material with rapid hemostasis and high biosafety is realized.

CN122075770APending Publication Date: 2026-05-26MEI HOSPITAL UNIV OF CHINESE ACAD OF SCI +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610366243.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-03-24
Publication Date
2026-05-26

Smart Images

  • Figure CN122075770A_ABST
    Figure CN122075770A_ABST
Patent Text Reader

Abstract

The invention discloses ionic cross-linked starch hemostatic powder and a preparation method and application thereof.The preparation method includes the steps that carboxymethyl starch with the substitution degree not smaller than 0.3 is dissolved in deionized water to be continuously stirred, a metal ion solution is quantitatively and dropwise added into the solution to obtain floccules, the floccules are centrifuged, washed and freeze-dried, and the ionic cross-linked starch hemostatic powder is obtained; the ionic cross-linked starch hemostatic powder is prepared. The preparation process is mild in reaction condition, a chemical cross-linking agent with poor biological safety is not needed, the process is simple and environment-friendly, and large-scale production is easy to realize.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical materials technology, specifically relating to an ion-crosslinked starch hemostatic powder, its preparation method, and its application. Background Technology

[0002] Traumatic bleeding is a leading cause of acute hemorrhagic shock and trauma-related death, especially in wartime trauma, traffic accidents, and complex surgical procedures. Failure to control bleeding promptly and effectively can rapidly lead to circulatory failure and multiple organ dysfunction, seriously threatening patient life. Clinical studies have shown that the timeliness of bleeding control is closely related to patient prognosis, and early hemostatic intervention can significantly reduce mortality and complication rates. However, in moist, irregular, and non-compressible wound conditions, traditional hemostatic methods often fail to achieve rapid and stable hemostasis. Therefore, developing hemostatic materials with rapid hemostatic capabilities, good biocompatibility, and suitability for complex wound environments is of significant clinical importance and practical necessity for improving the success rate of trauma treatment and patient prognosis.

[0003] Natural polysaccharide materials have attracted widespread attention in the field of wound hemostasis due to their wide availability and good biocompatibility. Among them, plant-derived starch has become a popular research topic due to its low price, low immunogenicity, and biodegradability. However, existing methods for preparing starch hemostatic materials mostly employ chemical emulsification and cross-linking reactions, which typically require surfactants and chemical cross-linking agents and rely on large amounts of organic solvents. This type of preparation method is not only complex in process and subject to harsh operating conditions, but also leaves behind organic solvent and cross-linking agent residues that are difficult to completely remove, potentially causing tissue irritation or posing biosafety risks. Furthermore, the use of organic solvents is detrimental to environmental protection, increases solvent recovery and treatment costs, and limits the greening and large-scale application of the process. In addition, the emulsification and cross-linking process is highly sensitive to reaction conditions and process parameters, easily leading to fluctuations in product particle size and performance, poor batch stability, and difficulty in meeting the quality consistency requirements of medical devices.

[0004] Therefore, there is an urgent need to develop a novel starch material and its preparation method that is safe and environmentally friendly in preparation process, does not require the use of large amounts of organic solvents and chemical cross-linking agents, and is suitable for hemostatic applications. Summary of the Invention

[0005] The purpose of this section is to outline some aspects of embodiments of the present invention and to briefly describe some preferred embodiments. Simplifications or omissions may be made in this section, as well as in the abstract and title of this application, to avoid obscuring the purpose of these documents; however, such simplifications or omissions should not be construed as limiting the scope of the invention.

[0006] In view of the problems existing in the above and / or prior art, the present invention is proposed.

[0007] Therefore, the purpose of this invention is to overcome the shortcomings of the prior art and provide an ion-crosslinked starch hemostatic powder, its preparation method, and its application.

[0008] To solve the above-mentioned technical problems, the present invention provides the following technical solution: a method for preparing ion-crosslinked starch hemostatic powder, characterized in that it includes: Carboxymethyl starch with a degree of substitution of not less than 0.3 was dissolved in deionized water and stirred continuously. A metal ion solution was quantitatively added dropwise to the above solution to obtain flocculent material. The flocculent material was centrifuged, washed, and freeze-dried to prepare ion-crosslinked starch hemostatic powder.

[0009] In a preferred embodiment of the preparation method described in this invention, the degree of substitution of the carboxymethyl starch is 0.3 to 1.

[0010] In a preferred embodiment of the preparation method described in this invention, the concentration of carboxymethyl starch dissolved in deionized water is 5~50 mg / mL.

[0011] In a preferred embodiment of the preparation method described in this invention, the metal ions in the metal ion solution include one of calcium ions, magnesium ions, cerium ions, and zinc ions.

[0012] In a preferred embodiment of the preparation method described in this invention, the concentration of the metal ion solution is 0.5~3 mL / min.

[0013] In a preferred embodiment of the preparation method described in this invention, the continuous stirring speed is 300~1000 rpm.

[0014] In a preferred embodiment of the preparation method described in this invention, the mass ratio of carboxymethyl starch to metal ions is 1~3:1.

[0015] Another objective of this invention is to overcome the shortcomings of the prior art and provide an ion-crosslinked starch hemostatic powder obtained by a preparation method.

[0016] As a preferred embodiment of the ion-crosslinked starch hemostatic powder of the present invention, the liquid absorption ratio of the ion-crosslinked starch hemostatic powder is 12.9~18.5.

[0017] Another objective of this invention is to overcome the shortcomings of the prior art and provide an application of ion-crosslinked starch hemostatic powder obtained by a preparation method in hemostatic materials.

[0018] Beneficial effects of this invention: (1) This invention provides a method for preparing an ion-crosslinked starch hemostatic material. The method involves dissolving highly substituted carboxymethyl starch in deionized water, and then, while the carboxymethyl starch solution is continuously stirred, quantitatively adding a certain concentration of metal ion solution to the starch solution. Through metal ion coordination and electrostatic interaction, flocculent material is formed. Finally, the flocculent material is centrifuged, washed, and freeze-dried to obtain an ion-crosslinked biodegradable starch hemostatic powder. The preparation process uses mild reaction conditions, does not require the use of chemical crosslinking agents with poor biosafety, and is simple, environmentally friendly, and easy to scale up for production.

[0019] (2) The ion-crosslinked hemostatic powder prepared in this invention has good water absorption properties, can quickly absorb water from the blood, concentrate coagulation factors, and promote rapid coagulation. The hemostatic powder particles swell upon absorbing water, and the particles rapidly crosslink into a network structure through electrostatic and ion coordination interactions, physically sealing the bleeding wound and synergistically enhancing the coagulation effect of the hemostatic powder. The ion-crosslinked starch-based hemostatic powder degrades into small molecules such as glucose in the wound environment, which are absorbed by the human body, resulting in high biocompatibility. Attached Figure Description

[0020] To more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings used in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort. Wherein: Figure 1 Photograph of the ion-crosslinked starch hemostatic powder prepared in Example 1 of this invention; Figure 2 These are photographs of experimental phenomena from Embodiment 1 of the present invention; Figure 3 The image shown is a scanning electron microscope image of the ion-crosslinked starch hemostatic powder prepared in Example 1 of this invention. Figure 4 Photographs showing experimental phenomena in comparison to the present invention; Figure 5 Here are scanning electron microscope images of the starch hemostatic powder prepared in the comparative example of this invention; Figure 6 This invention demonstrates the in vitro coagulation properties of the ion-crosslinked starch hemostatic powder prepared in Example 1 of the present invention, the starch-based hemostatic powder prepared in the control group, and commercially available starch-based hemostatic powder. Detailed Implementation Method 3 To make the above-mentioned objects, features and advantages of the present invention more apparent and understandable, the specific embodiments of the present invention will be described in detail below with reference to the examples in the specification.

[0022] Many specific details are set forth in the following description in order to provide a full understanding of the invention. However, the invention may also be practiced in other ways different from those described herein, and those skilled in the art can make similar extensions without departing from the spirit of the invention. Therefore, the invention is not limited to the specific embodiments disclosed below.

[0023] Secondly, the term "one embodiment" or "embodiment" as used herein refers to a specific feature, structure, or characteristic that may be included in at least one implementation of the present invention. The phrase "in one embodiment" appearing in different places in this specification does not necessarily refer to the same embodiment, nor is it a single or selective embodiment that is mutually exclusive with other embodiments.

[0024] Unless otherwise specified, all raw materials used in the embodiments of this invention are commercially available. See Table 1 for details.

[0025] Table 1

[0026] Determination of the degree of substitution of sodium carboxymethyl starch: The carboxyl group in sodium carboxymethyl starch is converted to -COOH under strong acid conditions, and the carboxyl content is determined by titration with standard NaOH solution. Accurately weigh approximately 0.2 g of modified highly substituted sodium carboxymethyl starch, add 25 mL of 0.1 mol / mL hydrochloric acid solution, stir at room temperature for 30 minutes, add 2-3 drops of methyl red-bromocresol green mixed indicator, and titrate with standard NaOH solution (concentration: [missing information]). C Titrate with NaOH solution (unit: mol / L). When the solution changes from red to gray and remains so for 30 seconds, record the volume of the NaOH solution. V, (Unit: mL)

[0027] The blank control experiment did not add sodium carboxymethyl starch, but all other procedures were exactly the same. The volume of NaOH solution was recorded. V 空白 (Unit: mL). The degree of carboxymethyl substitution (DS) is calculated according to formulas (1) and (2).

[0028] Formula (1) in Formula (2) Hemostatic material liquid absorption test: Approximately 20 mg of hemostatic powder was placed in a 6 cm diameter filter sieve (160 mesh). The sieve containing the powder was soaked in deionized water for 1 minute, and excess water on the sieve was quickly absorbed with filter paper. The mass of the sieve containing the absorbed powder was then weighed. The initial mass of the hemostatic powder was recorded as m0, and the mass of the hemostatic powder after liquid absorption was recorded as m. The liquid absorption ratio of the hemostatic powder was calculated according to formula (3).

[0029] Liquid absorption ratio = Formula (3) In vitro coagulation characterization of hemostatic materials: 1 mL of sodium citrate-anticoagulated rat whole blood was taken and mixed with 0.05 mol / L calcium chloride solution. The mixture was vortexed and the natural coagulation time of the recalcified blood at 37°C was controlled to be 9-11 minutes. 10 mg of ion-crosslinked biodegradable hemostatic powder and 100 μL of recalcified rat whole blood were added to a centrifuge tube, mixed thoroughly, and incubated at 37°C. 1 mL of PBS solution (pH 7.4) was added at fixed time points (1 minute, 3 minutes, and 5 minutes), and the coagulation status was observed.

[0030] Example 1 This embodiment provides a method for preparing ion-crosslinked starch hemostatic powder, specifically as follows: (1) Add 52.2 mL of isopropanol to a 250 mL three-necked flask, stir magnetically, add 2.34 mL of deionized water, 9 g of commercially available carboxymethyl starch, and 4.86 g of sodium hydroxide in sequence, heat to 32 °C and react for 0.5 hours, then continue to heat to 48 °C, stir vigorously, slowly add 5.4 g of chloroacetic acid dissolved in 5.4 mL of isopropanol solution, react for 0.5 hours after the addition is complete, finally heat to 68 °C and react for 4 hours, filter the reaction system to collect the solid, wash repeatedly with 85% ethanol 3 times, add 1 mL of glacial acetic acid, and finally wash once with 95% ethanol, dry under vacuum at 60 °C for 8 hours and collect the sample to obtain carboxymethyl starch with a degree of substitution of 0.3.

[0031] (2) At room temperature, take 1.0 g of the above carboxymethyl starch with a degree of substitution of 0.3 and add it to 100 mL of deionized water. Stir until the carboxymethyl starch is completely dissolved to obtain solution A. (3) Take 1.0 g of anhydrous calcium chloride and dissolve it in 50 mL of deionized water to obtain solution B; (4) Keep solution A stirred at a speed of 600 rpm, and add solution B dropwise to solution A at a rate of 1.5 mL / min. After the addition is complete, continue the reaction for 30 minutes.

[0032] (5) Centrifuge the reaction product at 1000 rpm for 3 minutes, remove the supernatant, wash with deionized water, centrifuge again to remove the supernatant, repeat the operation once, freeze-dry the obtained solid and crush it to obtain starch-based hemostatic powder.

[0033] Figure 1 The biodegradable hemostatic powder prepared in Example 1 was tested to have a liquid absorption ratio of 16.5.

[0034] Figure 2 The photograph shows the experimental phenomena of Example 1. Highly substituted sodium carboxymethyl starch forms a homogeneous solution in water, and after calcium ion cross-linking assembly, a flocculent precipitate is obtained.

[0035] Figure 3 The image shows a scanning electron microscope image of the biodegradable hemostatic powder prepared in Example 1. The hemostatic powder exhibits a micron-scale sheet-like structure with a larger specific surface area, which significantly improves its liquid absorption ratio and is beneficial for enhancing its coagulation performance.

[0036] Example 2 (1) Add 52.2 mL of isopropanol to a 250 mL three-necked flask, stir magnetically, add 2.34 mL of deionized water, 9 g of commercially available carboxymethyl starch, and 4.86 g of sodium hydroxide in sequence, heat to 32 °C and react for 0.5 hours, then continue to heat to 48 °C, stir vigorously, slowly add 5.4 g of chloroacetic acid dissolved in 5.4 mL of isopropanol solution, react for 0.5 hours after the addition is complete, finally heat to 68 °C and react for 4 hours, filter the reaction system to collect the solid, wash repeatedly with 85% ethanol 3 times, add 1 mL of glacial acetic acid, and finally wash once with 95% ethanol, vacuum dry at 60 °C for 8 hours and collect the sample, repeat the above modification operation once to obtain carboxymethyl starch with a degree of substitution of 0.5.

[0037] (2) At room temperature, take 3.0 g of the above-mentioned carboxymethyl starch with a degree of substitution of 0.5 and add it to 100 mL of deionized water. Stir until the carboxymethyl starch is completely dissolved to obtain solution A. (3) Take 1.0 g of anhydrous magnesium chloride and dissolve it in 50 mL of deionized water to obtain solution B; (4) Solution A is kept under stirring at a speed of 800 rpm and a dropping speed of 0.5 mL / min.

[0038] (5) Centrifuge the reaction product at 1000 rpm for 3 minutes, remove the supernatant, wash with deionized water, centrifuge again to remove the supernatant, repeat the operation once, freeze-dry the obtained solid and crush it to obtain starch-based hemostatic powder.

[0039] The hemostatic powder in Example 2 had an absorption ratio of 13.4.

[0040] Example 3 (1) Add 52.2 mL of isopropanol to a 250 mL three-necked flask, stir magnetically, add 2.34 mL of deionized water, 9 g of commercially available carboxymethyl starch, and 4.86 g of sodium hydroxide in sequence, heat to 32 °C and react for 0.5 hours, then continue to heat to 48 °C, stir vigorously, slowly add 5.4 g of chloroacetic acid dissolved in 5.4 mL of isopropanol solution, react for 0.5 hours after the addition is complete, finally heat to 68 °C and react for 4 hours, filter the reaction system to collect the solid, wash repeatedly with 85% ethanol 3 times, add 1 mL of glacial acetic acid, and finally wash once with 95% ethanol, vacuum dry at 60 °C for 8 hours and collect the sample, repeat the above modification operation 5 times to obtain carboxymethyl starch with a degree of substitution of 1.0.

[0041] (1) At room temperature, take 2.0 g of the above carboxymethyl starch with a degree of substitution of 1.0 and add it to 100 mL of deionized water. Stir until the carboxymethyl starch is completely dissolved to obtain solution A. (2) Take 1.0 g of anhydrous cerium chloride and dissolve it in 50 mL of deionized water to obtain solution B; (3) Solution A is kept under stirring at a speed of 500 rpm and a dropping speed of 1.0 mL / min.

[0042] (4) Centrifuge the reaction product at 1000 rpm for 3 minutes, remove the supernatant, wash with deionized water, centrifuge again to remove the supernatant, repeat the operation once, freeze-dry the obtained solid and crush it to obtain starch-based hemostatic powder.

[0043] The hemostatic powder in Example 3 had an absorption ratio of 12.9.

[0044] Example 4 (1) Add 52.2 mL of isopropanol to a 250 mL three-necked flask, stir magnetically, add 2.34 mL of deionized water, 9 g of commercially available carboxymethyl starch, and 4.86 g of sodium hydroxide in sequence, heat to 32 °C and react for 0.5 hours, then continue to heat to 48 °C, stir vigorously, slowly add 5.4 g of chloroacetic acid dissolved in 5.4 mL of isopropanol solution, react for 0.5 hours after the addition is complete, finally heat to 68 °C and react for 4 hours, filter the reaction system to collect the solid, wash repeatedly with 85% ethanol 3 times, add 1 mL of glacial acetic acid, and finally wash once with 95% ethanol, vacuum dry at 60 °C for 8 hours and collect the sample, repeat the above modification operation 4 times to obtain carboxymethyl starch with a degree of substitution of 0.8.

[0045] (2) At room temperature, take 1.0 g of carboxymethyl starch with a degree of substitution of 0.8 and add it to 100 mL of deionized water. Stir until the carboxymethyl starch is completely dissolved to obtain solution A. (3) Take 3.0 g of anhydrous zinc chloride and dissolve it in 50 mL of deionized water to obtain solution B; (4) Solution A is kept under stirring at a speed of 400 rpm and a dropping speed of 3.0 mL / min.

[0046] (5) Centrifuge the reaction product at 1000 rpm for 3 minutes, remove the supernatant, wash with deionized water, centrifuge again to remove the supernatant, repeat the operation once, freeze-dry the obtained solid and crush it to obtain starch-based hemostatic powder.

[0047] The hemostatic powder in Example 4 had an absorption ratio of 18.5.

[0048] Comparative Example 1 (1) At room temperature, 1.0 g of commercially available carboxymethyl starch with a degree of substitution of 0.1 was added to 100 mL of deionized water and stirred until homogeneous. Due to the low degree of substitution of carboxymethyl starch, the carboxymethyl starch would not dissolve. The resulting mixture was denoted as mixture A. (2) Take 1.0 g of anhydrous calcium chloride and dissolve it in 50 mL of deionized water to obtain solution B; (3) While mixing A, keep stirring at a speed of 600 rpm and add solution B dropwise to mixture A at a rate of 1.5 mL / min. After the addition is complete, continue the reaction for 30 minutes.

[0049] (4) Centrifuge the reaction product at 1000 rpm for 3 minutes, remove the supernatant, wash with deionized water, centrifuge again to remove the supernatant, repeat the operation once, freeze-dry the obtained solid and crush it to obtain starch-based hemostatic powder.

[0050] The hemostatic material absorption capacity of Examples 1-4 and Comparative Example 1 was tested, and the test results are shown in Table 2.

[0051] Table 2

[0052] In vitro coagulation characterization of hemostatic materials was performed on the examples and comparative examples. The blank group was not treated in any way, i.e. no hemostatic powder was added, while the commercially available group was given 10 mg of commercially available hemostatic powder (Xunning, Chongqing Lianbai Bochao Medical Device Co., Ltd., National Medical Device Registration Certificate 20203140664).

[0053] like Figure 4 As shown, the low-substituted sodium carboxymethyl starch cannot form a homogeneous solution in water, and it cannot form a flocculent precipitate under the same experimental conditions, indicating that there are not enough carboxyl groups to participate in the ionic cross-linking reaction.

[0054] like Figure 5 As shown, the product of the reaction of low-substituted sodium carboxymethyl starch is an irregular granular structure, which is different from the plate-like structure of the product of the reaction of high-substituted sodium carboxymethyl starch.

[0055] like Figure 6 As shown, the blank group received no treatment. After 5 minutes, PBS solution was added, and the solution turned blood red, indicating that the blood had not yet clotted after recalcification. In the experimental group, PBS solution was added after 1 minute, and the solution was clear and transparent, indicating that the blood in the experimental group had completely clotted within 1 minute. Similarly, the control group had not clotted after 5 minutes; the commercially available group showed no clotting after 3 minutes and clotted after 5 minutes. Compared with samples prepared from low-substituted carboxymethyl starch and commercially available hemostatic products, the hemostatic powder prepared in Example 1 showed significantly improved hemostatic properties.

[0056] Low-substituted sodium carboxymethyl starch cannot effectively produce specific sheet-like structures through ionic crosslinking. Its liquid absorption ratio is significantly lower than that of ionicly crosslinked high-substituted sodium carboxymethyl starch. Existing technologies for crosslinking starch primarily utilize epichlorohydrin chemical crosslinking. This emulsification reaction involves emulsifiers and requires heating, resulting in a complex preparation process. Furthermore, the subsequent washing of the emulsifier involves large amounts of organic solvents. Epichlorohydrin itself has an irritating odor, and if not completely washed away, the residues are biotoxic.

[0057] This invention forms a cross-linked network structure through direct metal coordination between metal ions and the carboxyl groups in sodium carboxymethyl starch. It only requires an aqueous solution of sodium carboxymethyl starch and an aqueous solution of metal ions, without the need to introduce organic solvents, and the reaction can be completed at room temperature.

[0058] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all such modifications or substitutions should be covered within the scope of the present invention.

Claims

1. A method for preparing an ion-crosslinked starch hemostatic powder, characterized in that: include, Carboxymethyl starch with a degree of substitution of not less than 0.3 was dissolved in deionized water and stirred continuously. A metal ion solution was quantitatively added dropwise to the above solution to obtain flocculent material. The flocculent material was centrifuged, washed, and freeze-dried to prepare ion-crosslinked starch hemostatic powder.

2. The preparation method according to claim 1, characterized in that: The degree of substitution of the carboxymethyl starch is 0.3 to 1.

3. The preparation method according to claim 2, characterized in that: The carboxymethyl starch is dissolved in deionized water. The concentration of carboxymethyl starch in the aqueous solution is 5~50 mg / mL.

4. The preparation method according to claim 1, characterized in that: The metal ions in the metal ion solution include one of calcium ions, magnesium ions, cerium ions, and zinc ions.

5. The preparation method according to claim 4, characterized in that: The concentration of the metal ion solution is 0.5~3 mL / min.

6. The preparation method according to claim 1, characterized in that: The continuous stirring speed is 300~1000 rpm.

7. The preparation method according to claim 1, characterized in that: The mass ratio of carboxymethyl starch to metal ions is 1~3:

1.

8. The ion-crosslinked starch hemostatic powder obtained by the preparation method according to any one of claims 1 to 7.

9. The starch hemostatic powder as described in claim 8, characterized in that: The liquid absorption ratio of the ion-crosslinked starch hemostatic powder is 12.9~18.

5.

10. The application of the ion-crosslinked starch hemostatic powder as described in claim 9 in hemostatic materials.